• Tue, July 25, 2023
Gregory Renza Maintained (VRCA) at Buy with Increased Target to $14 on, Jul 25th, 2023
Gregory Renza of RBC Capital, Maintained "Verrica Pharmaceuticals Inc." (VRCA) at Buy with Increased Target from $11 to $14 on, Jul 25th, 2023.
Gregory has made no other calls on VRCA in the last 4 months.
There is 1 other peer that has a rating on VRCA. Out of the 1 peers that are also analyzing VRCA, 0 agree with Gregory's Rating of Hold.
This is the rating of the analyst that currently disagrees with Gregory
- Oren Livnat of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $11 on, Monday, July 17th, 2023
